The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

21.6% Esophageal cancer has a 21.6% five-year survival rate. The esophagus is the muscular tube that transports food from the throat to the stomach. Risk factors for esophageal cancer include ...

Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Intestinal metaplasia does not cause any symptoms by itself, but having it may increase your risk of stomach or esophageal cancer. Genetic factors, diet, and gut bacteria can all contribute to the ...

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

It famously helps to cleanse the system of toxins—and even affects how your genes operate, according to California ...

By studying biomarkers known to be involved in gastrointestinal cancers, researchers have developed a biomarker algorithm that, when combined with a noninvasive method to collect esophageal cells for ...

staging system of the International Union Against Cancer (UICC). 11 Patients with a tumor in the esophagus or a tumor with an epicenter within 5 cm of the esophagogastric junction and extension ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and ...